Venous Ethanol for Ventricular Tachycardia (VELVET) Clinical Trial

This study is looking at new ways to treat Ventricular Tachycardia (VT), a fast and irregular heartbeat, in people with Ischemic Cardiomyopathy (heart muscle damage from blocked arteries). It compares two treatments: Catheter Ablation (a procedure using heat to destroy faulty heart tissue) alone, versus Catheter Ablation combined with Venous Ethanol. Venous Ethanol involves injecting ethanol into veins near the heart to help stop VT. You might be able to join if you are 18-85 years old, have an implanted defibrillator (ICD), have Ischemic Cardiomyopathy, and have experienced VT episodes in the last six months. The study will measure if these treatments reduce VT recurrence, hospitalizations for heart problems, and severe complications over 12 months. The current status of this study is unclear.

Study design: This is a comparative effectiveness randomized clinical trial, meaning participants will be randomly assigned to one of two treatment groups. The study aims to enroll 156 participants.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: Participants will be followed for 12 months after treatment to check for VT recurrence, hospitalizations, and complications.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Venous Ethanol for Ventricular Tachycardia

Recruiting

PHASE2Ages 18–85InterventionalTreatment

The Methodist Hospital Research Institute

~156 participants

Updated 2026-07-24 on ClinicalTrials.gov

What's tested:Venous ethanolCatheter ablation

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Ventricular tachycardia recurrence

Measured over 0-12 months

+3 more outcomes measured

Conditions

Ventricular Tachycardia

Ischemic Cardiomyopathy

Where it's being run

1 sites across 1 states

Texas1

Study leadership

Miguel Valderrabano, MD · PRINCIPAL_INVESTIGATOR · The Methodist Hospital Research Institute

Who to contact

Iris Melissa Alanis

[email protected]

7134416548

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Male and female, ages of 18 and 85 years and with a prior ICD implant

Diagnosed with ischemic cardiomyopathy: Prior myocardial infarction (pathological Q waves or imaging evidence of regional myocardial akinesis/thinning in the absence of a non-ischemic cause)

One of the following VT events (within last 6 months): a) ≥3 episodes of VT treated with anti-tachycardia pacing (ATP) or anti-arrhythmic drugs; b) ≥1 appropriate ICD shocks; c) ≥3 VT episodes within 24 hr; d) sustained VT below detection rate of the ICD documented by EKG/cardiac monitor

Patients deemed candidates for RF ablation of VT

Able and willing to comply with pre-, post-, and follow-up requirements

Willing to sign the informed consent

Exclusion

Creatinine clearance \<25 cc/min (using Cockcroft-Gault equation) except for patients on dialysis. (Contrast induced nephropathy is irrelevant in end-stage renal disease patients on dialysis, in whom the concern for contrast-induced renal dysfunction is not there since there is no chance of further kidney damage). Additionally, patients on dialysis will be excluded from the imaging sub-study.

Left ventricular (LV) ejection fraction ≤10%

Mobile LV thrombus on echocardiography

Absence of vascular access to the LV

Disease process likely to limit survival to \<12 months

New York Heart Association class IV heart failure

Cardiac surgery within the past 2 months (unless VT was incessant),

Acute coronary syndrome in the past 2 months (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on EKG)

Another reversible cause of VT (e.g. electrolyte abnormalities, drug-induced arrhythmia)

Severe aortic stenosis or mitral regurgitation with a flail leaflet

Pregnancy

Unwilling or unable to provide informed consent

Covid-19 positive testing within 14 days of randomization procedure

Enrolled, or planning to get enrolled, in another research study during his/her participation on the Velvet trial

What this trial measures

Ventricular tachycardia recurrence0-12 months
Detection of VT on defibrillator
Hospitalization for cardiac causes0-12 months
Severe procedural complications0-12 months
Severe procedural complications include bleeding requiring transfusion, stroke or systemic embolization, pericardial tamponade, myocardial infarction, and vascular complications requiring surgery, plus cardiogenic shock requiring unplanned mechanical support.
Death0-12 months

Trialytics